17α-Estradiol — ein moderner Inhibitor der 5α-Reductase

F, Hevert

doi:10.1007/978-3-642-57191-6_117

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Von dem für die AGA entscheidend wichtigen Enzym 5a−Reduk− tase sind zwei Isoformen bekannt [33,34] [35,36], das heißt, das Pharmakon besitzt in therapeutischen Dosen keine Hormonwir− kung. Zur besseren Abgrenzung gegen das hormonell wirksame 17b−Estradiol sollte durchgehend der Name Alfatradiol verwen− det werden.…”

Section: Introductionunclassified

Alfatradiol (0,025 %) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern

Wozel¹,

Narayanan²,

Jäckel³

et al. 2005

Akt Dermatol

View full text Add to dashboard Cite

Androgenetic alopecia (AGA), also referred to as male pattern baldness, is the most common cause of hair loss in both sexes in adulthood. An option for topical treatment that selectively tar− gets the metabolic pathways involved in the balding process is alfatradiol, an estrasterid without hormonal activity. In a drug monitoring study, efficacy and safety of alfatradiol (0.025 %) was assessed in 233 patients with AGA (192 women, aged 14 ± 76 years, and 41 men, aged 17 ± 56 years). After 7.5 months of treat− ment, trichograms of 112 patients (92 women, 20 men) were evaluated. Under treatment with alfatradiol the proportion of frontal anagen hair increased statistically significantly, in wom− en from 69 % to 77 % (means) and in men from 56 % to 65 %. The proportion of telogen hair decreased accordingly. In 12 % of wom− en and 21 % of men a further decline in the number of anagen hair was observed. Merely three patients (1,3 %) reported mild local adverse reactions. In conclusion, Alfatradiol appears to be ef− fective and safe in the topical treatment of AGA in both men and women.

show abstract

Section: Introductionunclassified